We are proud to have been voted ‘Most Productive Pharmaceutical Company’ for three consecutive years. With four new drugs approved in Europe in the last four years and five drugs in late stage development in oncology, our ongoing commitment to patients is clear.
Fighting cancer with focused teams
By harnessing our expertise we are making great strides forward. At Janssen, our discovery teams are integrated with our world-class development and commercialization capabilities. This maximizes the potential of our discovery efforts.
These integrated teams are organized within Disease Area Strongholds (DAS). These are disease areas of intense focus where we are cultivating deep expertise. This is also where all of our early- and late-stage research, development and commercialization capabilities are strategically aligned against common goals and objectives. (Learn more about Disease Area Strongholds.)
Our priority DAS teams focus on hematologic malignancies, prostate cancer, and lung cancer. Another area of focus is colorectal cancer.